P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs
- 14 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 114 (14) , 1860-1870
Abstract
P2Y12 antagonists are the standard in antiplatelet therapy but their potential effects on functional myocardial recovery and cardioprotection post-myocardial infarction (MI) are unknown. We investigated in a preclinical model of MI whether ticagrelor and clopidogrel differently affect cardiac repair post-MI. Pigs either received: 1) clopidogrel (600mg; 75mg/qd); ticagrelor (180mg; 90mg/bid); and 3) placebo-control. MI was induced by mid-left anterior descending coronary artery balloon occlusion (60min) and animals received the maintenance doses for the following 42days. Serial cardiac magnetic resonance was performed at day3 and day42 for the assessment of global and regional cardiac parameters. We determined cardiac AMP-activated protein kinase (AMPK), Akt/PKB, aquaporin-4, vascular density and fibrosis. In comparison to controls, both P2Y12 antagonists limited infarct expansion at day3 although ticagrelor induced a further 5% reduction (p < 0.05 vs. clopidogrel) whereas edema was only reduced by ticagrelor (≈23% p < 0.05). Scar size decreased at day42 in ticagrelor-treated pigs vs. controls but not in clopidogrel-treated pigs. Left ventricular ejection fraction was higher 3days post-MI in ticagrelor-treated pigs and persisted up to day42 (p < 0.05 vs. post-MI). Regional analysis revealed that control and clopidogrel-treated pigs had severe and extensive wall motion abnormalities in the jeopardized myocardium and a reduced myocardial viability that was not as evident in ticagrelor-treated pigs (χ2 p < 0.05 vs. ticagrelor). Only ticagrelor enhanced myocardial AMPK and Akt/PKB activation and reduced aquaporin-4 levels (p < 0.05 vs. control and clopidogrel). No differences were observed in vessel density and fibrosis markers among groups. Ticagrelor is more efficient than clopidogrel in attenuating myocardial structural and functional alterations post-MI and in improving cardiac healing. These benefits are associated with persistent AMPK and Akt/PKB activation.Keywords
Funding Information
- PNS (SAF2016-76819-R)
- PNS (2015-71653-R)
- Spanish Ministry of Science and Innovation
- FEDER
- Instituto de Salud Carlos III CIBERCV (CN16/11/00411)
- Muy Ilustrísima Administración
- Hospital de la Santa Creu I Sant Pau
- AstraZeneca
- Generalitat of Catalunya (2014SGR1303)
- Fundacion Investigación Cardiovascular
This publication has 40 references indexed in Scilit:
- A small molecule AMPK activator protects the heart against ischemia–reperfusion injuryJournal of Molecular and Cellular Cardiology, 2011
- The in-situ pig heart with regional ischemia/reperfusion — Ready for translationJournal of Molecular and Cellular Cardiology, 2011
- The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusionInternational Journal of Cardiology, 2011
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLOS Biology, 2010
- Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe Lancet, 2010
- Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis modelThrombosis and Haemostasis, 2010
- No-Reflow PhenomenonCirculation, 2002
- Recommendations for Standards in Transthoracic Two-Dimensional Echocardiography in the Dog and CatJournal of Veterinary Internal Medicine, 1993
- Risk Stratification and Survival after Myocardial InfarctionNew England Journal of Medicine, 1983
- The stunned myocardium: prolonged, postischemic ventricular dysfunction.Circulation, 1982